Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma  by Lee, Terry T. et al.
General
Thoracic Surgery
Radical pleurectomy/decortication and intraoperative
radiotherapy followed by conformal radiation with or
without chemotherapy for malignant pleural mesothelioma
Terry T. Lee, MDa
Darcie L. Everett, BSb
Hui-Kuo G. Shu, MD, PhDa
Thierry M. Jahan, MDc
Mack Roach III, MDa
Joycelyn L. Speight, MD, PhDa
Robert B. Cameron, MDb
Theodore L. Phillips, MDa
Albert Chan, RTTa
David M. Jablons, MDb
See related editorial on page
1074.
Objectives: We performed a retrospective review of the efficacy and morbidity of
radical pleurectomy/decortication and intraoperative radiotherapy followed by ex-
ternal beam radiation therapy with or without chemotherapy for diffuse malignant
pleural mesothelioma.
Methods: A total of 32 patients with diffuse malignant pleural mesothelioma were
initially evaluated between January 1995 and September 2000. Three patients were
excluded from analysis because of unresectable disease. Two patients died postop-
eratively, and one patient had recurrent disease previously treated at an outside
institution. Of the remaining 26 patients included in the analysis, 24 received
intraoperative radiotherapy. External beam radiation therapy was generally started 1
to 2 months after resection and delivered by means of 3-dimensional conformal
radiation therapy or with inverse treatment planning intensity-modulated radiation
therapy. When given, chemotherapy consisted of 2 to 3 cycles of cyclophospha-
mide, doxorubicin (Adriamycin), and cisplatin initiated 1 to 2 months after com-
pletion of radiation.
Results: At the time of data analysis, 5 of 26 patients were alive. The median
follow-up was 9.7 months (range, 2-67.6 months). The median overall survival and
progression-free interval from the time of the operation were 18.1 and 12.2 months,
respectively. The Kaplan-Meier estimates of overall survival and freedom from
progression at 1 year were 64% and 50%, respectively. The site of failure was
mostly locoregional. However, there were 4 abdominal failures and 1 contralateral
lung failure.
Conclusions: Radical pleurectomy/decortication with aggressive radiotherapy with
or without chemotherapy might offer an alternative treatment option to those who
cannot tolerate extrapleural pneumonectomy.
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Diffuse malignant pleural mesothelioma(DMPM) is an invasive, locally aggres-sive tumor that is almost always fatal.Tumor progression in the chest is typi-cally manifested by increasing mass sizeand pleural effusion, causing physical
compression of the ipsilateral lung and respiratory compro-
mise. Although distant metastasis occurs with advanced
disease, inadequate local control has been the main cause of
death.
Approximately 2500 new cases of DMPM are diagnosed
each year, and the incidence has been slowly rising.1,2 The
best-defined and most common risk factor is asbestos ex-
posure. The main reason for the increase in incidence is due
to the long latency period (40 years) and the prevalence of
occupational exposure to asbestos in the mid-20th century.
Surgical intervention has been the most common treat-
ment approach for this disease. One surgical approach is
extrapleural pneumonectomy (EPP), which has been advo-
cated by some as a way of achieving maximal cytoreduc-
tion. This procedure involves en bloc removal of the pleura
(parietal and visceral), the entire ipsilateral lung, and por-
tions of the pericardium, diaphragm, or both. Historically,
this approach has met with a high operative and in-hospital
mortality (on the order of 15%-20%). However, in highly
specialized centers the perioperative mortality rates have
been reported to be less than 5%.3-5 Another surgical ap-
proach is radical pleurectomy/decortication (P/D), which
allows debulking of the tumor while preserving the ipsilat-
eral lung. In this procedure the parietal pleura is dissected
from the endothoracic fascia, and an incision is made to
allow exposure and decortication of the visceral pleura.
Portions of the diaphragm and pericardium are also resected
with reconstruction as needed. Although this approach is
technically difficult, it is generally less morbid and better
tolerated than EPP, with perioperative mortality rates of less
than 5%.6-8 As a single modality, the results of aggressive
surgical resections have been disappointing, with median
survivals of less than 1 year in most series.3,4,6,7
Radiation therapy has also been used for the treatment of
DMPM. However, the results of radiation therapy alone
have been disappointing and generally used for pallia-
tion.9,10 Because of the amount of tumor that is often present
at diagnosis, it is difficult to deliver a tumoricidal dose of
radiation to the volume at risk (entire ipsilateral pleural
surface) without damaging a significant volume of the un-
derlying lung.
Chemotherapy has been tried with limited success. Cur-
rently available chemotherapy agents, such as platinum-
containing regimens, doxorubicin-containing regimens, or
both, have poor response rates on the order of 20% to
30%.11,12 Newer agents, such as multitargeted antifolate, in
combination with cisplatin in early clinical trials produced
partial response rates of 40%.13 Gemcitabine alone has been
disappointing. A phase II trial by the Cancer and Leukemia
Group B demonstrated no antitumor activity.14 However, a
combination therapy with gemcitabine and cisplatin might
be more effective and has been shown to have a response
rate of 47%.15
Multimodality therapy has been tried to improve survival
over single-modality treatment. Different combinations of
therapies, including surgical intervention (EPP or radical
P/D) with intraoperative brachytherapy, intrapleural chemo-
therapy, postoperative radiation therapy, systemic chemo-
therapy, and/or intraoperative photodynamic therapy, have
been used.5,8,16-22 Sugarbaker and colleagues,5 at the Dana-
Farber Cancer Institute, have the largest series of patients
with pleural mesothelioma treated with combined modality.
Their approach involves the use of EPP, followed by post-
operative chemoradiation. The most recent update reports a
median survival of 19 months, with even better outcomes in
certain subgroups of patients. In particular, node-negative
patients with epithelial histologic characteristics who had
complete resection have achieved median survivals of 51
months. However, because their series only included pa-
tients capable of tolerating EPP, a built-in selection bias
might be present.
At the University of California, San Francisco (UCSF),
radical P/D with adjuvant radiation therapy has been used to
allow patients with a less favorable cardiopulmonary status
to undergo resection. However, preservation of the lung
might lead to an increased incidence of radiation pneumo-
nitis if treated with even moderate doses of radiation. In-
traoperative radiation therapy (IORT) at the time of resec-
tion can be used as a radiation boost to partially circumvent
this problem. By delivering a single large fraction of radi-
ation at the time of the operation, a modest dose of postop-
erative external beam radiation might be adequate to obtain
local control while sparing lung parenchyma relative to
full-dose postoperative radiation. Adjuvant chemotherapy
was often given to suitable patients after the completion of
external beam radiation. This series represents a retrospec-
tive review of patients treated at UCSF by using this ap-
proach.
Methods
A total of 32 patients were evaluated for multimodality treatment
at UCSF between January 1995 and September 2000. After insti-
tutional review board approval had been obtained, data regarding
patient outcome were obtained from hospital charts, the Social
Security death index, and the patients’ outside physicians. In-
formed consent was obtained for all patients for the surgical and
radiotherapeutic components of this treatment. Patients were fully
counseled on the risks of intraoperative and postoperative radiation
therapy.
Before acceptance for treatment, histologic confirmation of
malignant mesothelioma was made at UCSF. Preoperative require-
ments were normal liver function test results and creatinine levels,
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as well as an estimated Karnofsky performance status of 70% or
greater. Parameters on pulmonary function tests included a forced
expiratory volume in 1 second of greater than 1.5 L and a diffusing
capacity for carbon monoxide in the lungs of greater than 50%.
Echocardiography with or without sestamibi scans were used to
evaluate cardiac function before the operation. Finally, chest and
upper abdominal computed tomographic (CT) scans and other
radiologic studies, as clinically indicated, were used to evaluate
resectability of the primary tumor and to rule out extrathoracic
disease.
At the time of the operation, 3 of 32 patients were found to have
unresectable disease. The remaining 29 patients underwent at-
tempted definitive resections. One patient was excluded from the
analysis because she had recurrent disease. There were 2 (7%)
postoperative deaths. One patient died of a pulmonary embolus 1
day after the operation. One patient died of acute respiratory arrest
with hypotension and subsequent multiorgan failure 10 days after
the operation. The 26 patients who underwent radical P/D form the
basis of this review.
Patients underwent resection through a posterolateral thora-
cotomy with an excision of the sixth rib and a second intercostal
incision at the ninth intercostal space, as necessary. Isolated
lung ventilation was used. For postoperative pain, thoracic
epidural analgesia was used. A complete extrapleural dissection
was performed on all patients. Occasionally, patients with lo-
cally extensive disease through the endothoracic fascia received
limited en bloc chest wall resection. Thirty-one percent (8/26)
of patients also underwent resections of the diaphragm with
bovine pericardium or prosthetic reconstruction when indicated
to achieve at least R1 resection. All efforts were made to avoid
entry into the peritoneum. Patients underwent complete visceral
pleurectomy, including clean dissection of the pulmonary artery
and hilar structures. Twenty-three percent (6/26) of patients
underwent prior talc pleurodesis, which did not preclude com-
plete visceral pleurectomy. Sixty-two percent (16/26) of pa-
tients underwent mediastinal and hilar nodal sampling. Typical
nodes sampled included levels 4, 6, and 7 and 9, 10, and 11. As
a routine, radical mediastinal and hilar node dissection was not
performed. All patients had disease-free mediastinal nodes (1
cm), as determined with preoperative CT and positron emission
tomography, and thus did not undergo preoperative mediasti-
noscopy. Patients were monitored postoperatively in an inten-
sive care unit setting.
Of these 26 patients, 24 received IORT at the time of resection.
One patient did not receive IORT because of logistic difficulties
and the other because of hemodynamic instability during the
operation. Before December 1997, IORT was delivered through a
Clinac 2300 device (Varian, Palo Alto, Calif) in the Department of
Radiation Oncology at UCSF. This required transportation of the
patient from the operating room to the department. All subsequent
IORTs were performed on the Mobetron (Intraop Medical, Santa
Clara, Calif), a mobile intraoperative electron therapy unit in the
operating room. All areas difficult to encompass by means of
conformal radiation treatment planning were treated with IORT.
These areas included the major fissure, the pericardium, and the
diaphragm. The average number of sites treated with IORT was
3.3, with a range of 2 to 6 sites. The median dose was 15 Gy
(range, 5-15 Gy) by using 4-, 6-, or 9-MeV electrons with a typical
bolus of 5 to 10 mm.
Postoperative radiation therapy was given to 24 patients (one
patient died before receiving external beam radiation therapy,
and the other was medically unstable) starting approximately 1
to 2 months after the operation. Before November 1997, exter-
nal beam radiation therapy was delivered by means of 3-dimen-
sional conformal radiation therapy (3D-CRT; 14 patients).
Since then, intensity-modulated radiation therapy (IMRT) with
inverse treatment planned on the Corvus system (Nomos Corp,
Sewickley, Pa) was used (10 patients). The goal of external
beam radiation therapy was to treat the ipsilateral pleural sur-
face and all surgical scars while sparing the underlying lung
parenchyma. The radiation oncologist determined the external
beam radiation dose on the basis of the coverage of the target
volume, as well as the ability to spare the underlying lung
parenchyma. The median prescription dose of external beam
radiation therapy was 41.4 Gy (range, 30.1-48.8 Gy). Chemo-
therapy, when given, consisted of cyclophosphamide, doxoru-
bicin, and cisplatin for 2 to 3 cycles, beginning 1 to 2 months
after radiotherapy. Adjuvant treatment parameters are summa-
rized in Table 1.
After completion of radiation therapy, patients were seen in
follow-up every 3 months. New baseline CT scans and chest
radiographs were obtained 1 to 2 months after completion of
postoperative radiation. Serial chest radiographs were used to monitor
patients every 3 to 4 months with CT investigation of evolving
abnormalities. Patients also underwent annual CT evaluations.
TABLE 1. Treatment parameters
Treatment factors
No. of IORT sites, n  17
Median (mean) 3 (3.3)
Range 2-6
IORT doses used per site (cGy)
Median (mean) 1500 (1270)
Range 500-1500
Patients who completed post operative EBRT
Yes 24
No 2
Method of post operative EBRT
3D-CRT 14
IMRT 10
Post operative EBRT prescribed doses,
n  24 (cGy)
Median (mean) 4135 (4029)
Range 3008-4880
Post operative EBRT maximum doses for 3D-CRT,
n  14 (cGy)
Median (mean) 4950 (5017)
Range 3893-6475
Post operative EBRT maximum doses for IMRT,
n  10 (cGy)
Median (mean) 5829 (5571)
Range 3008-7500
Patients who received chemotherapy
Yes 12
No 14
EBRT, External beam radiation therapy.
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All statistical analyses were performed with a statistical soft-
ware package (STATA; Computing Resource Center, Santa
Monica, Calif). Overall survival time and progression-free interval
were calculated from the time of the initial operation by using the
Kaplan-Meier method. Failures were scored at the time of radio-
graphic evidence of tumor progression. Univariate analyses of
prognostic factors were performed with either a Cox proportional
hazards model or a log-rank test.
Results
Patient Characteristics and Treatment Parameters
The overall patient and tumor characteristics are summa-
rized in Table 2. A majority (16/26) of tumors were right
sided. Eleven of 26 patients had a history of both smoking
and asbestos exposure. As expected, the predominant his-
tologic type was epithelial (n  19). One patient had purely
sarcomatous histologic characteristics, and 5 patients had
mixed histologic features. On the basis of the 1997 Amer-
ican Joint Committee on Cancer TNM staging, 18 of 26
patients had stage I disease, and the remaining 8 patients
had stage III disease. Three patients had pathologic evidence
of nodal involvement. One patient had a level 8 node, and the
other 2 had intrapulmonary nodes involved with tumor.
At the time of thoracotomy, 65% (17/26) of patients had
complete removal of gross tumor (R0), whereas 31% (8/26)
had microscopic disease (R1). One patient (4%) underwent
incomplete resection (R2). This patient received treatment
with IORT.
Survival, Local Control, and Prognostic Factors
Of the 26 patients, 5 were alive at the time of analysis. The
median follow-up was 9.7 months from the time of radical
P/D (range, 2-67.6 months). The median overall survival
from the time of the operation was 18.1 months (Figure 1).
The percentage of patients still alive at 1 and 2 years was
64% and 32%, respectively. A majority of deaths were due
to tumor progression. Other causes of death included a
pulmonary embolism in one patient after an unrelated sur-
gical procedure (transurethral resection of prostate) approx-
imately 2 months after radical P/D, and one patient com-
mitted suicide at 5 months without any evidence of disease.
The median progression-free interval from the time of
the operation was 12.2 months (Figure 2). Progression-free
survival at 1 and 2 years was 50% and 22%, respectively.
The site of failure was mostly locoregional along the pre-
vious site of surgically resected pleural disease. In one
patient the failure occurred at a chest tube site that was not
included in the postoperative radiation therapy treatment
volume. This patient was taken to the operating room for
resection, and the area was further treated with electron
beam therapy. He then died of local progression 9 months
after completion of radiation therapy. There were 4 abdom-
inal failures. Twenty-five percent (2/8) of patients with
diaphragm reconstruction had abdominal failure versus 11%
(2/18) of patients without reconstruction. One patient had fail-
ure in the contralateral lung with hematogenous metastasis.
A number of potential prognostic factors, including R0
versus R1, stage, histologic type, nodal involvement,
Karnofsky performance status, radiation dose, and number
of IORT sites, were tested by means of univariate analysis.
Only a lower number of IORT sites was found to be pre-
dictive of overall survival, with a hazard ratio of 2.15 (95%
confidence interval, 1.05-4.40). The same potential prog-
nostic factors were then analyzed by means of univariate
analyses for progression-free interval as the end point. There
were no variables that predicted progression-free interval. Mul-
tivariate analysis was not performed because of the absence of
multiple significant univariate prognostic factors.
Morbidity and Mortality From Therapy
Mean estimated blood loss from the operation was 1400 mL
(range, 500-3500 mL). The median hospitalization was 9
TABLE 2. Patient and tumor characteristics
Characteristics
Evaluable patients 26
Patients who received IORT 24
Sex (male/female) 21/5
Age (y)
Median (mean) 69 (68)
Range 45-84
Karnofsky performance status
Median (mean) 90 (85)
Range 60-90
History of asbestos exposure
Yes 17
No 9
History of tobacco use
Yes 17
No 9
History of prior talc pleurodesis
Yes 6
No 20
Side of lung
Left 10
Right 16
Histology
Epithelial 19
Sarcomatous 1
Mixed 5
Not specified 1
AJCC TNM stage
I 18
II 0
III 8
AJCC T Stage
1 1
2 18
3 7
Node involved
Yes 3
No 23
IORT, Intraoperative radiation therapy.
General Thoracic Surgery Lee et al
1186 The Journal of Thoracic and Cardiovascular Surgery ● December 2002
G
TS
days, with a range of 7 to 18 days. Chest tubes were
removed on the fourth to fifth postoperative day (range, day
2-12). Major postoperative complications included atrial
fibrillation in 11% (3/26) of patients and persistent air leak,
defined as greater than 7 days, in 4% (1/26) of patients.
The primary morbidity of postoperative external beam
radiation therapy was radiation-induced pneumonitis.
Symptoms of pneumonitis (eg, fever and persistent cough)
were noted in 17% (4/24) of patients at 3 to 7 months after
the completion of radiation therapy. One patient had symp-
toms consistent with pericarditis at 6 months’ follow-up. In
all 5 of these cases, symptoms were self-limiting and sub-
sequently resolved with conservative management. Finally,
1 patient had an esophageal stricture that ultimately required
Figure 1. Kaplan-Meier curves for overall survival.
Figure 2. Kaplan-Meier curves for progression-free interval.
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balloon dilatation. However, this case was complicated by
the fact that a previous course of radiation therapy was
given at an outside institution before radical P/D. The pa-
tient was subsequently treated with postoperative external
beam radiation therapy at UCSF. This resulted in a high
dose of radiation to the esophagus, which most likely is the
reason for the complication.
Discussion
Local control appears to be the main problem in treating
malignant pleural mesothelioma. Surgical intervention
alone (either EPP or radical P/D) is clearly not enough to
eradicate all local disease. This has led to an increased
interest in adjuvant therapy. Although pilot studies on the
use of intraoperative photodynamic therapy as adjuvant
therapy were promising,8,18 a phase III trial showed no
apparent benefit on either progression-free or overall sur-
vival.20 Rusch21 reported on the use of postoperative in-
trapleural chemotherapy after radical P/D with moderate
improvements in local control and survival. This approach
might also be problematic in some settings. Intrapleural
chemotherapy is limited by its diffusion capacity, prevent-
ing efficient treatment of disease that is more than a few
millimeters deep. Intrapleural instillation of chemotherapy
has an additional problem postoperatively; the pleural space
often becomes adherent and leads to poor distribution of the
drug.
The current treatment method at UCSF has involved
IORT to the areas at highest risk for residual disease at the
time of resection. IORT allows delivery of a single high
dose of electron therapy to the target while limiting the dose
to normal tissue. The underlying lung parenchyma can be
spared because of the rapid dose fall off of the electron
beam. Postoperatively, the pleural surface is given an addi-
tional dose by means of external beam radiation therapy to
spare the underlying lung parenchyma.
The median prescribed dose of external beam radiation
was 41.4 Gy (range, 30.1-48.8 Gy). The dose was selected
on the basis of the coverage of the target volume and on the
tolerance dose to the lung. Kutcher and colleagues23 have
previously published a technique for the treatment of pleural
mesothelioma using a combination of photons and electrons
to spare a significant portion of the lung. A similar tech-
nique was used at UCSF before November 1997 with 3D-
CRT. However, with IMRT with inverse planning, it might
be possible to improve the coverage of the pleural surface
and decrease toxicity. An additional advantage of IMRT is
the inherent heterogeneous dose distribution. This often
results in a higher dose within the center of the target
volume. Therefore, although the prescription dose (ie, min-
imum dose to target volume) might be similar between the
3D-CRT and IMRT, the maximum dose within the target
volume is significantly higher in the IMRT plan. The me-
dian and mean maximum doses in the IMRT plans were
58.3 and 55.7 Gy, respectively. The median and mean
maximum doses in the 3D-CRT plans were 49.5 and 50.2
Gy, respectively. The number of patients treated in this
series was too small to conclude any difference in survival
between 3D-CRT and IMRT.
Progression of disease in the chest remains a major
problem with this approach. Better local control through
dose escalation would be extremely difficult without in-
creasing complication rates with currently available tech-
nology. Proton therapy or helical tomotherapy might poten-
tially increase dose to the tumor without exceeding lung
tolerance.
The complication rates were acceptable. The periopera-
tive mortality rate was 7%, and there were few postopera-
tive morbidities. Four percent (1/24) of patients had radia-
tion pneumonitis in the IMRT group, whereas 13% (3/24) of
patients in the 3D-CRT group experienced radiation pneu-
monitis. Four percent (1/24) of patients in the latter group
experienced pericarditis, and 4% had esophageal stricture. It
is our clinical impression that IMRT might be better at
sparing normal tissue toxicity, but a more rigorous compar-
ison should be performed.
The multimodality treatment at UCSF differs in some
very important ways from the extensive experience at Dana
Farber Cancer Institute, as reported by Sugarbaker and
colleagues.5,19 Unlike the EPP used by Sugarbaker, a radical
P/D was used at UCSF. The decision to perform a lung-
preserving procedure in this group of patients was not based
solely on their ability to tolerate pneumonectomy but rather
based on a bias that P/D is better tolerated in patients with
an essentially incurable disease. The median age in our
series was 69 years compared with 57 years in the Sugar-
baker series, possibly contributing to an increased mortality
rate. Although the number of patients to date is small, the
overall results appear to be comparable with those reported
by Sugarbaker and colleagues, with a median overall sur-
vival of 18.1 compared with 19 months.
Sugarbaker and colleagues5 showed, through subset anal-
ysis, prolonged median survival of 26 months with epithe-
lial histology. The results from our series did not show a
significant difference in overall survival or progression-free
interval between epithelial histology and sarcomatous-
mixed histology. The small number of patients most likely
contributed to the inability to detect a correlation. The
higher number of IORT fields treated significantly inversely
correlated with overall survival. An increased number of
IORT fields reflects a greater extent of residual disease,
which might account for the difference in survival.
Rusch and coworkers22 reported their results of 61 pa-
tients treated with EPP and postoperative external beam
radiation (median dose of 54 Gy). The median survival was
17 months, and the 3-year overall survival was 27%. For the
19 patients who had stage I or II disease, the median
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survival was 33.8 months. For the 42 patients with stage III
or IV disease, it was 10 months. The locoregional recur-
rence rate was only 13%, suggesting a benefit of a combined
modality approach with higher doses of radiation, but dis-
tant metastases occurred in 57% of patients. Although pa-
tients with mesothelioma are commonly believed to die of
local recurrences, this study illustrates the need for systemic
therapy. In our series 19% of patients had distant recur-
rence, also demonstrating the potential of mesothelioma for
distant metastasis.
The preliminary results of this experience are disappoint-
ing when analyzed for long-term survival and recurrence.
The small size of the series, older median age, mixed
histologic types, and proportion of R1 resections could
account for part of the discrepancy between this experience
and those reported in the literature. In addition, although a
majority of patients had nodal sampling, pathologic staging
not based on node dissection might not be precise. Inadver-
tent understaging might account for survival differences.
In summary, traditional single-modality treatment for
DMPM has been disappointing. P/D can offer complete
resections (R0) in a majority of cases, even in the setting of
bulky disease. Combined with adjuvant chemoradiation,
this therapeutic scheme might offer an alternative to those
who cannot tolerate EPP as part of a combined modality
approach. In addition, we intend to use our experience with
P/D as a platform for developing adjuvant combined mo-
dality therapies with novel biologic agents. We hope that
effective cytoreduction can be achieved with lung preser-
vation, acceptable morbidities, and a high percentage of
complete resection, while allowing targeted therapies to
control microscopic residual disease and systemic microme-
tastasis. The use of P/D in a multimodality setting with
improvements in biologics, cytotoxics, and radiation tech-
niques might ultimately enhance long-term survival.
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